Investigational drug · Phase 2
LM-350
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "LM-350"
First trial start
2025
Aug 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LM-350", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LM-350" as an intervention, largest first.
LaNova Medicines LimitedIndustry
NCT07112222 · 80 participants (planned) · Start Aug 28, 2025 · Primary completion Jun 30, 2028
Drug: LM-350 for injection · For: Malignant Tumors
Sites: Wollongong, Australia; Adelaide, Australia; Frankston, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Malignant Tumors
- LBL-007AlcestobartPhase 38 trials
BeOne Medicines (BeiGene) · Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- MK-2010LM-299Phase 24 trials
Merck & Co. · Advanced Solid Tumors, Malignant Neoplasm, Malignant Tumors
- LM-364Phase 22 trials
LaNova Medicines Limited · Advanced Solid Tumor Cancer, Malignant Tumors
- LM101Phase 21 trial
LaNova Medicines Limited · Malignant Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.